MedTrace Logo

Assessment of Opioid Analgesia in Sickle Cell

NCT00513864 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2014-12-23

No results posted yet for this study

Summary

To develop and validate a non-invasive, in vivo, phenotyping method for CYP2D6 using the non-injurious neuroselective electrical stimulation technique: pain perception threshold/pain tolerance threshold (PPT/PTT) in children and adolescents with sickle cell disease.

Conditions

Interventions

DRUG

Dextromethorphan

one time dose - 0.3mg/kg PO

DRUG

Codeine

one time dose - 2mg/kg PO

DRUG

Morphine

one time dose - 0.15mg/kg IV

Sponsors & Collaborators

  • Children's National Research Institute

    lead OTHER

Principal Investigators

  • Julia C. Finkel, M.D. · Children's National Medical Center-PPRU

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
7 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-11-30
Primary Completion
2012-03-31
Completion
2012-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00513864 on ClinicalTrials.gov